4279 |
Left Main PCI; Who and How? |
Mamas Mamas |
Apr. 19. 23 |
4278 |
MultiVessel Disease Revascularization; Consensus and Gaps in 2023 |
Sripal Bangalore |
Apr. 19. 23 |
4277 |
Left Main Revascularization; Consensus and Gaps in 2023 |
David Joel Cohen |
Apr. 19. 23 |
4276 |
PCSK9 Inhibitor: Effect of Alirocumab on CV Events and Mortality After ACS |
Hanbit Park |
Apr. 08. 22 |
4275 |
Landscape of Lipid Management Following an ACS Event |
Choongki Kim |
Apr. 08. 22 |
4274 |
How is SAPIEN 3 Valve Design Connected to Clinical Benefit? |
Young-Guk Ko |
Apr. 08. 22 |
4273 |
Strategies of IVUS-Guided Left Main PCI with SYNERGY MEGATRON¢â BP Stent |
Jeehoon Kang |
Apr. 08. 22 |
4272 |
SYNERGY MEGATRON – Advancing Your Large Proximal Vessel Strategy for Improved Outcomes |
Huay Cheem Tan |
Apr. 08. 22 |
4271 |
Comparison of 2 Different Paclitaxel-coated Balloons in Coronary In-stent Restenosis: A Randomized Controlled Trial |
Eun-Seok Shin |
Apr. 08. 22 |
4270 |
Influence of Baseline HbA1c and Antiplatelet Therapy on 1-year Vein Graft Outcome |
Qiang Zhao |
Apr. 08. 22 |